Rubra Medicaments has informed that the meeting of the Board of Directors of the Company is scheduled on 11/08/2022 to consider and approve Standalone Unaudited Financial Results along with limited review report of the Company for the quarter ended June 30, 2022. The Company shall intimate to the exchange the unaudited Financial Results upon the conclusion of the Board Meeting as required by SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; Reappointment of Sneha Thakur (DIN: 07805202) as an Independent Director for a further period of 5 years from July 7, 2022 till July 6, 2027 subject to approval of members in forthcoming Annual General Meeting; To fix the dates of Book Closure for Annual General Meeting; To decide the time, venue and date of Annual General Meeting.
The above information is a part of company’s filings submitted to BSE.
